Kura Oncology (NASDAQ:KURA) Insider Francis Burrows Sells 23,726 Shares of Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Francis Burrows sold 23,726 shares of the firm’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $9.78, for a total transaction of $232,040.28. Following the completion of the transaction, the insider directly owned 33,735 shares in the company, valued at $329,928.30. This represents a 41.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kura Oncology Price Performance

Shares of KURA opened at $9.84 on Friday. Kura Oncology, Inc. has a 12 month low of $5.41 and a 12 month high of $12.49. The company has a market cap of $856.28 million, a P/E ratio of -3.97 and a beta of 0.21. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. The stock has a fifty day moving average price of $10.63 and a 200 day moving average price of $8.36.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.The firm had revenue of $20.75 million during the quarter, compared to analyst estimates of $17.48 million. On average, research analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Analysts Set New Price Targets

KURA has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research note on Wednesday, October 8th. Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a report on Friday, December 5th. Barclays reissued an “overweight” rating and set a $28.00 price objective (up from $11.00) on shares of Kura Oncology in a research note on Monday, November 24th. JMP Securities reaffirmed a “market outperform” rating and set a $24.00 target price on shares of Kura Oncology in a research report on Monday, October 20th. Finally, Wedbush reaffirmed an “outperform” rating and set a $38.00 target price (up from $36.00) on shares of Kura Oncology in a report on Friday, November 14th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $26.57.

Institutional Trading of Kura Oncology

Several hedge funds and other institutional investors have recently modified their holdings of KURA. EverSource Wealth Advisors LLC grew its holdings in shares of Kura Oncology by 392.8% during the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock valued at $34,000 after buying an additional 3,072 shares in the last quarter. State of Wyoming acquired a new stake in Kura Oncology during the 1st quarter worth about $48,000. PNC Financial Services Group Inc. grew its stake in Kura Oncology by 127.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock valued at $60,000 after acquiring an additional 3,769 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Kura Oncology by 471.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after purchasing an additional 9,958 shares during the period. Finally, Pallas Capital Advisors LLC lifted its position in shares of Kura Oncology by 32.2% in the second quarter. Pallas Capital Advisors LLC now owns 13,304 shares of the company’s stock worth $77,000 after purchasing an additional 3,241 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.